Medtronic has announced the launch of the Aristotle Mini guidewire following US Food and Drug Administration (FDA) 510(k) clearance in August this year.
As stated in a press release, this clearance follows the recent US FDA approval of the Onyx 12 liquid embolic system and further expands Medtronic’s offerings for the treatment of chronic subdural haematoma (cSDH), adding a lower-profile option to the Aristotle guidewire portfolio that is designed to help physicians reliably reach the anatomy they need to treat.
For procedures like middle meningeal artery (MMA) embolisation—during which physicians often need to navigate small, distal vessels before delivering therapy—Aristotle Mini is intended to support access to these anatomies, bringing lower-profile navigation together with embolic therapy.
Built on Medtronic’s proprietary microfabrication technology, Aristotle Mini seeks to provide the structural integrity, steerability and control physicians need, the company claims. The newly launched device is compatible with 0.013-inch inner diameter microcatheter workflows, and complements Medtronic neurovascular technologies like Marathon and Apollo microcatheters as well as Onyx liquid embolic systems.
“As the burden of cSDH continues to grow, physicians need access to a range of technologies that help them treat increasingly complex anatomy,” said Linnea Burman, senior vice president and president of the neurovascular business—part of the neuroscience portfolio—at Medtronic. “Therapy begins with access and, together with our broader portfolio of navigation, delivery and treatment technologies, Aristotle Mini reflects our commitment to advancing innovation across the entire neurovascular treatment journey.”
Aristotle Mini could also be utilised to support procedures involving arteriovenous malformations (AVMs) and dural arteriovenous fistulas (dAVFs), where physicians may need to navigate similarly small and distal vessels in the brain.
“MMA embolisation can involve anatomy that varies considerably from patient to patient,” said Adam Arthur, chief medical officer for Medtronic’s neurovascular business. “Having another lower-profile access option gives physicians more flexibility to choose the approach that best fits the anatomy and the procedure. Ultimately, that can help physicians deliver treatment more confidently and support better outcomes for patients with cSDH.”
Aristotle Mini will be introduced through a phased commercial launch, with broader availability planned following initial physician experience.
The Aristotle portfolio of guidewires was originally developed by Scientia Vascular, which Medtronic acquired in June 2026.
